home / stock / amgn / amgn news


AMGN News and Press, Amgen Inc. From 06/20/24

Stock Information

Company Name: Amgen Inc.
Stock Symbol: AMGN
Market: NASDAQ
Website: amgen.com

Menu

AMGN AMGN Quote AMGN Short AMGN News AMGN Articles AMGN Message Board
Get AMGN Alerts

News, Short Squeeze, Breakout and More Instantly...

AMGN - Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024  – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...

AMGN - Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...

AMGN - Where Will Amgen Be in 5 Years?

2024-06-20 08:15:00 ET Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500 's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, s...

AMGN - Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...

AMGN - Amgen: You Haven't Seen Anything Yet

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

AMGN - Top Dow Jones Stocks To Buy Today? 2 To Know

2024-06-17 10:09:54 ET The Dow Jones Industrial Average (DJIA) is a widely recognized stock market index that represents 30 large, publicly-owned companies based in the United States. These companies are leaders across diverse sectors, making the Dow a general indicator of the market&#x...

AMGN - Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting

2024-06-16 07:19:35 ET Summary Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and othe...

AMGN - FDA grants expanded approval for Amgen's Blincyto in ALL

2024-06-14 17:13:58 ET More on Amgen Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card Amgen Stock: Poised To Break Out (Technical Analysis) Amgen posts ...

AMGN - FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE PR Newswire BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Deat...

AMGN - Structure Therapeutics: Yet Another Potential GLP-1 Entrant

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

Previous 10 Next 10